Show simple item record

dc.contributor.authorTupler, Rossella
dc.contributor.authorPerini, Giovanni
dc.contributor.authorPellegrino, Maria Antonietta
dc.contributor.authorGreen, Michael R.
dc.date2022-08-11T08:09:36.000
dc.date.accessioned2022-08-23T16:37:12Z
dc.date.available2022-08-23T16:37:12Z
dc.date.issued1999-10-27
dc.date.submitted2009-04-02
dc.identifier.citation<p>Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12650-4.</p>
dc.identifier.issn0027-8424 (Print)
dc.identifier.pmid10535977
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38959
dc.description.abstractFacioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disorder characterized by an insidious onset and progressive course. The disease has a frequency of about 1 in 20,000 and is transmitted in an autosomal dominant fashion with almost complete penetrance. Deletion of an integral number of tandemly arrayed 3.3-kb repeat units (D4Z4) on chromosome 4q35 is associated with FSHD but otherwise the molecular basis of the disease and its pathophysiology remain obscure. Comparison of mRNA populations between appropriate cell types can facilitate identification of genes relevant to a particular biological or pathological process. In this report, we have compared mRNA populations of FSHD and normal muscle. Unexpectedly, the dystrophic muscle displayed profound alterations in gene expression characterized by severe underexpression or overexpression of specific mRNAs. Intriguingly, many of the deregulated mRNAs are muscle specific. Our results suggest that a global misregulation of gene expression is the underlying basis for FSHD, distinguishing it from other forms of muscular dystrophy. The experimental approach used here is applicable to any genetic disorder whose pathogenic mechanism is incompletely understood.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=10535977&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC23032/
dc.subjectBase Sequence
dc.subjectDNA Primers
dc.subjectDNA, Complementary
dc.subjectGene Expression Regulation
dc.subjectHumans
dc.subjectMolecular Sequence Data
dc.subjectMuscle Proteins
dc.subjectMuscular Dystrophy, Facioscapulohumeral
dc.subjectSubtraction Technique
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleProfound misregulation of muscle-specific gene expression in facioscapulohumeral muscular dystrophy
dc.typeJournal Article
dc.source.journaltitleProceedings of the National Academy of Sciences of the United States of America
dc.source.volume96
dc.source.issue22
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1788
dc.identifier.contextkey808554
html.description.abstract<p>Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disorder characterized by an insidious onset and progressive course. The disease has a frequency of about 1 in 20,000 and is transmitted in an autosomal dominant fashion with almost complete penetrance. Deletion of an integral number of tandemly arrayed 3.3-kb repeat units (D4Z4) on chromosome 4q35 is associated with FSHD but otherwise the molecular basis of the disease and its pathophysiology remain obscure. Comparison of mRNA populations between appropriate cell types can facilitate identification of genes relevant to a particular biological or pathological process. In this report, we have compared mRNA populations of FSHD and normal muscle. Unexpectedly, the dystrophic muscle displayed profound alterations in gene expression characterized by severe underexpression or overexpression of specific mRNAs. Intriguingly, many of the deregulated mRNAs are muscle specific. Our results suggest that a global misregulation of gene expression is the underlying basis for FSHD, distinguishing it from other forms of muscular dystrophy. The experimental approach used here is applicable to any genetic disorder whose pathogenic mechanism is incompletely understood.</p>
dc.identifier.submissionpathoapubs/1788
dc.contributor.departmentHoward Hughes Medical Institute, Program in Molecular Medicine
dc.source.pages12650-4


This item appears in the following Collection(s)

Show simple item record